| Medication review ratings | AKI Warning Stage 1 | AKI Warning Stage 2 | AKI Warning Stage 3 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Kidney recovery (SCr % above baseline) | ≤ 25% | >25% & <50% | ≥ 50% | ≤ 25% | >25% & <50% | ≥ 50% | ≤ 25% | >25% & <50% | ≥ 50% | |
| Median (Rating) | Median (Rating) | Median (Rating) | Median (Rating) | Median (Rating) | Median (Rating) | Median (Rating) | Median (Rating) | Median (Rating) | ||
| No past medical history | Not required | 1.5 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) |
| Med r/v at 3 days | 1.5 (I) | 2 (I) | 3.5 (E) | 2 (I) | 3 (E) | 4.5 (E) | 3 (I) | 3.5 (E) | 6.5 (D) | |
| Med r/v at 1–2 weeks | 2.5 (I) | 4 (E) | 7 (E) | 6 (D) | 7.5 (U) | 8 (A) | 7.5 (E) | 8 (E) | 8 (E) | |
| Med r/v at 1 month | 6.5 (E) | 7 (U) | 6.5 (U) | 7 (E) | 7 (U) | 6.5 (E) | 7 (U) | 6.5 (U) | 5.5 (E) | |
| Med r/v at 3 months | 7 (E) | 6 (E) | 5.5 (E) | 6.5 (E) | 4.5 (E) | 3.5 (E) | 5 (E) | 4 (E) | 2.5 (E) | |
| Chronic kidney disease | Not required | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) |
| Med r/v at 3 days | 3 (I) | 4 (E) | 5.5 (E) | 3 (E) | 4 (E) | 6.5 (E) | 3 (E) | 4 (E) | 4 (E) | |
| Med r/v at 1–2 weeks | 5.5 (E) | 8 (E) | 8 (A) | 7 (E) | 8 (A) | 8 (A) | 7.5 (E) | 8.5 (A) | 8.5 (A) | |
| Med r/v at 1 month | 8 (A) | 8 (A) | 6.5 (E) | 8 (A) | 7 (A)* | 5 (E) | 7 (A) | 7 (A)* | 7 (A)* | |
| Med r/v at 3 months | 5.5 (U) | 3.5 (E) | 3.5 (E) | 5 (E) | 3 (E) | 2 (E) | 4.5 (E) | 3 (E) | 3 (E) | |
| Chronic heart failure | Not required | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) |
| Med r/v at 3 days | 4.5 (U) | 5 (U) | 7 (U) | 4 (E) | 5.5 (U) | 8 (A)* | 5 (E) | 6 (E) | 9 (A) | |
| Med r/v at 1–2 weeks | 8 (A) | 8.5 (A) | 9 (A) | 8 (A) | 8 (A) | 9 (A) | 9 (A) | 8.5 (A) | 8 (A)* | |
| Med r/v at 1 month | 7 (U) | 6 (E) | 5.5 (E) | 6 (U) | 6 (E) | 5 (E) | 5.5 (U) | 5 (E) | 3.5 (E) | |
| Med r/v at 3 months | 4 (E) | 3 (E) | 2.5 (I) | 4 (E) | 2.5 (E) | 2 (I) | 4 (E) | 2 (I) | 1.5 (I) | |
| Chronic kidney disease & chronic heart failure | Not required | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) |
| Med r/v at 3 days | 4.5 (E) | 6 (U) | 8 (A)* | 5.5 (E) | 6 (U) | 8 (A)* | 6 (E) | 8 (A)* | 9 (A) | |
| Med r/v at 1–2 weeks | 8 (A) | 9 (A) | 9 (A) | 9 (A) | 9 (A) | 9 (A) | 9 (A) | 9 (A) | 8 (A)* | |
| Med r/v at 1 month | 6 (E) | 6.5 (E) | 4.5 (D) | 6 (E) | 4.5 (E) | 3.5 (D) | 5.5 (E) | 4 (E) | 2.5 (E) | |
| Med r/v at 3 months | 3 (E) | 2.5 (E) | 2 (I) | 3 (E) | 2 (I) | 1.5 (I) | 2.5 (E) | 1.5 (I) | 1 (I) | |
| Other significant cardiovascular risk factors | Not required | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) |
| Med r/v at 3 days | 2.5 (I) | 3.5 (U) | 5 (E) | 3 (U) | 4 (E) | 6.5 (E) | 4 (U) | 4.5 (E) | 7 (A)* | |
| Med r/v at 1–2 weeks | 6 (U) | 7.5 (A)* | 8 (A) | 7 (E) | 8 (A) | 9 (A) | 8 (E) | 9 (A) | 9 (A) | |
| Med r/v at 1 month | 8 (A) | 8 (A) | 6.5 (E) | 8 (A) | 7.5 (A)* | 6 (E) | 8 (A) | 7.5 (A)* | 5.5 (D) | |
| Med r/v at 3 months | 6 (U) | 5 (E) | 3 (I) | 4.5 (U) | 3 (I) | 2 (I) | 5 (E) | 2.5 (I) | 1.5 (I) | |
| Markers of vulnerability | Not required | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) |
| Med r/v at 3 days | 3 (U) | 4 (U) | 6 (E) | 3 (U) | 4.5 (U) | 6 (U) | 4 (E) | 5.5 (U) | 8 (A)* | |
| Med r/v at 1–2 weeks | 6.5 (E) | 8 (A) | 8.5 (A) | 7 (E) | 8 (A) | 9 (A) | 8 (A)* | 9 (A) | 8 (A) | |
| Med r/v at 1 month | 8 (A) | 7 (A)* | 7 (E) | 8 (A) | 7.5 (A)* | 6.5 (E) | 8 (A) | 7.5 (E) | 6 (D) | |
| Med r/v at 3 months | 5 (E) | 4 (E) | 3.5 (E) | 4.5 (E) | 3.5 (E) | 3 (I) | 4 (E) | 3 (I) | 1.5 (I) | |
| Other markers of frailty | Not required | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) | 1 (I) |
| Med r/v at 3 days | 3 (U) | 4 (U) | 6 (E) | 3 (I) | 4 (U) | 6.5 (E) | 3 (E) | 5 (E) | 8 (A)* | |
| Med r/v at 1–2 weeks | 7 (U) | 7.5 (A) | 8 (A) | 7 (E) | 8 (A) | 9 (A) | 8 (E) | 9 (A) | 8.5 (A) | |
| Med r/v at 1 month | 8 (A) | 7.5 (U) | 6.5 (E) | 8 (A) | 7 (A)* | 6 (E) | 8 (A) | 7 (A)* | 5.5 (D) | |
| Med r/v at 3 months | 5.5 (D) | 5 (E) | 3 (E) | 5 (E) | 3 (U) | 2 (I) | 4.5 (E) | 3 (I) | 2 (I) |
The colour of each cell represents the result with the highest consensus. Grey cells are given where consensus was not reached. A = appropriate. A* = appropriate but with a lower average certainty. AKI = acute kidney injury. D = disagreement. E = equivocal. I = inappropriate. Med r/v = medication review. SCr = serum creatinine. U = agreement with uncertain benefit.